Immunovant (IMVT) PT Lowered to $24 at Truist Securities

Go back to Immunovant (IMVT) PT Lowered to $24 at Truist Securities

Raymond James Downgrades Immunovant (IMVT) to Market Perform

June 1, 2021 3:31 PM EDT

Raymond James analyst Danielle Brill downgraded Immunovant (NASDAQ: IMVT) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $15.16 yesterday.

... More

Guggenheim Downgrades Immunovant (IMVT) to Neutral

June 1, 2021 1:22 PM EDT

Guggenheim analyst Yatin Suneja downgraded Immunovant (NASDAQ: IMVT) from Buy to Neutral.

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $15.16 yesterday.

... More

Stifel Downgrades Immunovant (IMVT) to Hold

June 1, 2021 10:27 AM EDT

Stifel analyst Derek C. Archila downgraded Immunovant (NASDAQ: IMVT) from Buy to Hold with a price target of $9.00 (from $28.00).

The analyst commented, "This morning, IMVT provided an update indicating that IMVT-1401's LDL increases are due to the on-target reductions of albumin that... More